

ABSTRACT OF THE DISCLOSURE

Methods are disclosed for prophylactically and
5 chronically preventing symptomatic depression, neuronal
cell injury and cell death in systemic and neurological
conditions, populations with cerebrovascular risk
factors, and invasive vascular procedures, employing a
glycine-site antagonist at the NMDA (N-methyl-D-
10 aspartate) complex e.g., 2-phenyl-1,3-propanediol
dicarbamate (felbamate).